Somatropin - Saizen (EMD Serono) - Complete Research Paper

1. Summary

Saizen is a recombinant human growth hormone (rhGH, somatropin) manufactured by EMD Serono, Inc., a subsidiary of Merck KGaA. It received initial FDA approval in 1987, making it one of the earliest recombinant growth hormone products on the US market. Saizen's primary differentiator is the easypod electronic auto-injector—the first device in growth hormone therapy to provide automatic dose recording, adherence monitoring, and connectivity features.

FDA Approval: 1987 (Initial) Manufacturer: EMD Serono, Inc. (Rockland, MA), affiliate of Merck KGaA (Darmstadt, Germany) NDA: 019764

Key Clinical Features:

• Drug class: Recombinant human growth hormone (somatropin)
• Molecular weight: ~22,125 daltons (191 amino acids)
• Administration: Subcutaneous injection
• Half-life: ~2.0 hours (SC), ~0.6 hours (IV)
• Bioavailability: 70-90%
• Unique feature: easypod electronic auto-injector with connectivity

Primary Advantage: Saizen's easypod device represents a technological advancement in growth hormone delivery, providing electronic recording of injection history, automatic needle insertion, and cloud connectivity for adherence monitoring. The device was a 2007 Gold Medal recipient of the Medical Design Excellence Awards.

2. Mechanism of Action

Saizen functions identically to natural pituitary-derived human growth hormone.

Primary Mechanism:

1. GH Receptor Binding: Somatropin binds to GHR on target cells (liver, muscle, bone, adipose)
2. JAK2-STAT5 Activation: Receptor dimerization triggers JAK2 phosphorylation and STAT5 signaling
3. Gene Transcription: Growth-related gene expression induced
4. IGF-I Production: Hepatic IGF-I synthesis stimulated (primary mediator of growth effects)

Direct Effects:

• Skeletal growth at epiphyseal plates (pediatric)
• Muscle protein synthesis enhancement
• Bone metabolism stimulation
• Organ growth regulation

Metabolic Effects: | System | Effect | |---

Goal Relevance:

• Support growth in children with growth hormone deficiency to help them reach their full height potential.
• Enhance muscle growth and strength in adults with growth hormone deficiency for improved physical performance.
• Aid in fat loss by reducing visceral fat mass and boosting metabolism in individuals with growth hormone deficiency.
• Improve bone density and support skeletal health in adults with growth hormone deficiency to reduce the risk of fractures.
• Assist in tissue repair and recovery for individuals needing enhanced healing after injuries or surgeries.
• Boost energy levels and overall vitality in adults experiencing fatigue due to growth hormone deficiency.
• Enhance skin health and reduce signs of aging by promoting collagen production and cellular repair.
• Support joint health and mobility by improving flexibility and reducing joint pain in individuals with growth hormone deficiency.

-----|--------| | Protein | Increased synthesis, nitrogen retention, positive nitrogen balance | | Lipid | Enhanced lipolysis, reduced visceral fat mass | | Carbohydrate | Insulin resistance (dose-dependent), counter-regulatory to insulin | | Mineral | Increased calcium absorption, bone mineral density |

IGF-I Mediated Effects:

• Linear growth via chondrocyte proliferation
• Tissue repair and regeneration
• Anabolic effects on skeletal muscle

3. FDA-Approved Indications

Saizen has a focused indication profile compared to some other somatropin products.

Pediatric Indication:

Adult Indication:

Diagnostic Criteria for Adult GHD: Adults must meet ONE of the following:

1. Biochemical diagnosis of adult-onset GHD by two GH stimulation tests
2. Childhood-onset GHD confirmed as adult through provocative testing after completing linear growth

Note: Unlike some competitors (Genotropin, Humatrope, Norditropin), Saizen does not have FDA approval for:

• Turner syndrome
• Prader-Willi syndrome
• Small for Gestational Age (SGA)
• Idiopathic Short Stature (ISS)
• SHOX deficiency
• Noonan syndrome
• Chronic renal insufficiency (CRI)

4. Dosing and Administration

General Principles:

• Individualize dosage based on growth response and tolerability
• Subcutaneous administration only
• Rotate injection sites (thigh, abdomen, buttocks, upper arm)
• Divide weekly dose across multiple daily injections

Pediatric GHD Dosing:

Adult GHD Dosing:

Special Dosing Considerations:

• Elderly patients: Use lower starting dose and smaller increments
• Obese patients: Use non-weight-based dosing to reduce risk of adverse effects
• Women on oral estrogen: May require higher doses

Product Presentations:

easypod Compatible Cartridges:

• 8 mg/mL concentration
• 5.83 mg/mL concentration
• 1.5 mg/mL concentration

5. Pharmacokinetics

Absorption:

• Route: Subcutaneous injection
• Bioavailability: 70-90% (SC administration)
• Tmax: Not explicitly stated; typically 3-6 hours for somatropin products

Distribution:

• Volume of Distribution: 12.0 ± 1.08 L
• Distributes to liver, kidney, muscle, bone, target tissues

Metabolism:

• Classical protein catabolism
• Primary sites: Liver and kidneys
• No CYP450 enzyme involvement
• Proteolytic degradation to amino acid constituents

Elimination:

• Half-life (IV): ~0.6 hours
• Half-life (SC): ~2.0 hours
• Clearance (IV): 14.6 ± 2.8 L/hr

Comparison with Other Somatropin Products:

6. Side Effects and Adverse Reactions

Common Adverse Events:

Injection Site Reactions:

• Pain
• Numbness
• Redness
• Swelling

Systemic Effects (Adults):

• Peripheral edema
• Arthralgia
• Myalgia
• Paresthesia
• Hypoesthesia
• Headache
• Carpal tunnel syndrome

Metabolic Effects:

• Glucose intolerance (~10% of patients without pre-existing diabetes)
• Persistent abnormalities of glucose tolerance

Endocrine Effects:

• Hypothyroidism
• Fluid retention

Serious Adverse Reactions:

Pediatric-Specific:

• Slipped capital femoral epiphysis (SCFE)
• Intracranial hypertension (pseudotumor cerebri)
• Progression of scoliosis
• Pancreatitis (rare)

Prader-Willi Syndrome Patients: Fatalities reported in PWS patients with severe obesity, sleep apnea, or respiratory impairment. Saizen not indicated for PWS but warning applies.

Neoplasm Concerns:

• Increased risk of second neoplasms in childhood cancer survivors
• Meningiomas particularly increased in patients with brain/head radiation history
• Monitor for tumor recurrence in patients with history of malignancy

7. Drug Interactions

8. Contraindications

Absolute Contraindications:

Relative Contraindications/Precautions:

• History of malignancy (especially childhood cancer)
• Diabetes mellitus or impaired glucose tolerance
• Pre-existing intracranial hypertension
• Scoliosis
• Turner syndrome (fluid retention risk)

9. Special Populations

Pediatric Patients:

• Safety and efficacy established for GHD
• Monitor for SCFE symptoms (hip/knee pain, limp)
• Evaluate for intracranial hypertension
• Track linear growth response

Geriatric Patients:

• Limited data in elderly
• Use lower starting doses
• Smaller dose increments
• Increased sensitivity to adverse effects
• More prone to fluid retention and arthralgia

Pregnancy:

• Category B (Saizen label from prior classification)
• Use only if clearly needed
• No adequate controlled studies in pregnant women

Lactation:

• Unknown if excreted in human milk
• Caution advised
• Consider benefit to mother vs. risk to infant

Renal Impairment:

• Reduced clearance expected
• Use with caution
• May require dose adjustment

Hepatic Impairment:

• Reduced clearance expected
• Use with caution
• May require dose adjustment

10. Monitoring Parameters

Baseline Evaluation:

• Height and weight
• Bone age (pediatric)
• IGF-I level
• Thyroid function (free T4, TSH)
• Fasting glucose and HbA1c
• Fundoscopic examination
• Assessment for scoliosis (pediatric)

Ongoing Monitoring:

easypod Adherence Monitoring:

• Injection history available via device display
• Cloud upload capability (easypod connect)
• Physician can review compliance data

11. Cost and Availability

Pricing (United States, 2024-2025):

Patient Assistance Programs:

Connections for Growth (EMD Serono): Phone: 1-800-582-7989

Eligibility Restrictions:

• Co-pay programs NOT valid for Medicare, Medicaid, or government insurance
• PAP available only for uninsured or those whose insurance doesn't cover Saizen
• Annual renewal required

Alternative Savings:

• GoodRx: Starting around $281.45+ with discount card
• NiceRx: Flat $49/month program for eligible patients

Distribution:

• Available through specialty pharmacies
• easypod device distributed through Connections for Growth program

12. Clinical Evidence Summary

Bioequivalence: Saizen is therapeutically equivalent to other approved somatropin products based on:

• Identical amino acid sequence to endogenous GH
• Comparable pharmacokinetic profiles
• Similar efficacy outcomes in clinical trials

Pediatric GHD Efficacy:

• Significant improvement in height velocity
• Catch-up growth demonstrated
• Long-term height gains consistent with other somatropin products

Adult GHD Efficacy:

• Improved body composition (reduced fat mass, increased lean mass)
• Enhanced quality of life measures
• Improved bone mineral density
• Favorable lipid profile changes

easypod Adherence Data: The easypod connect system has generated real-world evidence demonstrating:

• Accurate recording of injection history
• Ability to identify non-adherent patients
• Correlation between adherence and growth outcomes
• Healthcare provider engagement improvement

13. Comparison with Alternatives

When to Choose Saizen:

1. Adherence concerns: easypod provides objective monitoring
2. Connected care: Healthcare providers want visibility into injection patterns
3. Technology preference: Patients comfortable with electronic devices
4. Adult GHD focus: Fewer indications may simplify coverage decisions

Limitations:

• Narrower indication profile than competitors
• Higher cost than biosimilar options
• easypod device adds complexity for some patients

14. Storage and Handling

Before Reconstitution (Vials):

• Store at room temperature: 15-30°C (59-86°F)
• Protect from light
• Do not freeze

After Reconstitution:

saizenprep/Cartridges:

• Before first use: Refrigerate
• After first use: Refrigerate; use within 21 days
• Do not freeze reconstituted product

easypod Device:

• Batteries: ~10 months (lithium), ~6 months (alkaline)
• Data stored permanently in device memory
• Keep device clean and dry

15. References

1. Saizen Prescribing Information. EMD Serono, Inc. Available at: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab750de2-3eda-411a-924e-00c499eda39b

2. FDA Drug Approval Package: Saizen NDA #019764. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/

3. Drugs.com. Saizen Package Insert / Prescribing Information. Available at: https://www.drugs.com/pro/saizen.html

4. EMD Serono. Connections for Growth Support Program. Available at: https://www.saizenus.com/healthcare-professionals/support-savings-for-patients/

5. GoodRx. Saizen 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/saizen

6. EMD Serono. easypod Auto-Injector Information. Available at: https://hcp.merckgroup.com/en/endocrinology/saizen/saizen-details/about-easypod.html

7. Dahlgren J. Easypod: a new electronic injection device for growth hormone. Expert Rev Med Devices. 2008;5(3):297-304.

8. Merck Serono. easypod Connect Platform Information. Available at: https://www.prnewswire.co.uk/news-releases/merck-serono-launches-easypod-connect-in-europe-144768165.html

9. BioSpace. EMD Serono Launches easypod. Available at: https://www.biospace.com/article/releases/emd-serono-inc-launches-easypod-r-new-electronic-growth-hormone-injection-device-/

10. RxList. Saizen (Somatropin) Drug Information. Available at: https://www.rxlist.com/saizen-drug.htm

Document compiled from FDA prescribing information, manufacturer resources, and clinical literature. Last updated: December 2024.

Status: PAPER 72 OF 76 COMPLETE

Next Paper: #73 - Somatropin (Nutropin)